îæ€çŽ¢
îæ€çŽ¢
î
AIM ImmunoTech Inc
AIMîãŠã©ãããªã¹ãã«è¿œå
0.257USD
+0.022+9.45%
çµå€Â 07-31 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
2.12Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现æ å ± AIM ImmunoTech Inc äŒæ¥å
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companyâs flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãAIM
äŒç€ŸåAIM ImmunoTech Inc
äžå Žæ¥Jul 12, 1996
æé«çµå¶è²¬ä»»è
ãCEOãEquels (Thomas K)
åŸæ¥å¡æ°21
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jul 12
æ¬ç€Ÿæåšå°2117 Sw Highway 484
éœåžOCALA
蚌åžååŒæNASDAQ OMX â NASDAQ Basic Amex
åœUnited States of America
éµäŸ¿çªå·32801
é»è©±çªå·13524487797
ãŠã§ããµã€ãhttps://aimimmuno.com/
äŒæ¥ã³ãŒãAIM
äžå Žæ¥Jul 12, 1996
æé«çµå¶è²¬ä»»è
ãCEOãEquels (Thomas K)
AIM ImmunoTech Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
ãããã質å
AIM ImmunoTech Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îAIM ImmunoTech Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ããMr. Thomas K. Equels, Esq., J.D.
AIM ImmunoTech IncïŒAIMïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2026Q1æç¹ã§ãAIM ImmunoTech Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯57瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ105.74Kã§ãå
šäœã®1.30%ãå ããŠããŸãã2025Q4ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-74291.00å¢å ããŠããŸãã